Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.55 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 2/20 | 0.48 |
| ▸ | JAK3 | P52333 | 3/20 | 0.48 |
| ▸ | JAK1 | P23458 | 3/20 | 0.48 |
| ▸ | SGK1 | O00141 | 1/20 | 0.47 |
| ▸ | TTK | P33981 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 2/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL589703 | 0.85 | JAK2 (0.48) | JAK2PDPK1HTR6JAK3TYK2 | |
| SCHEMBL592519 | 0.82 | JAK2 (0.50) | JAK2PDPK1KDM4ECYP3A4GAA | |
| SCHEMBL11614800 | 0.79 | JAK2 (0.56) | JAK2PDPK1KDM4ECYP3A4GAA | |
| SCHEMBL11699496 | 0.79 | JAK2 (0.60) | JAK2PDPK1KDM4ECYP3A4GAA | |
| SCHEMBL2661199 | 0.75 | JAK2 (0.64) | JAK2KDM4EGAA | |
| SCHEMBL16934639 | 0.74 | CDK7 (0.57) | JAK2PDPK1JAK3JAK1TYK2 | |
| SCHEMBL590142 | 0.73 | DYRK1A (0.44) | JAK2CYP3A4JAK3TTKTYK2 | |
| SCHEMBL15575131 | 0.72 | JAK2 (0.54) | JAK2PDPK1JAK3TYK2PRKD3 | |
| SCHEMBL3359889 | 0.71 | JAK2 (1.00) | JAK2PDPK1KDM4ECYP3A4GAA | |
| SCHEMBL12907246 | 0.71 | JAK2 (1.00) | JAK2PDPK1KDM4ECYP3A4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101594862-B | Substituted indazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-11-25 | — | — | CN | disclosed |
| WO-2015110467-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED N-(5-BENZENESULFONYL-1H-INDAZOL-3-YL)-BENZAMIDES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-07-30 | — | — | WO | disclosed |
| EP-2120932-B1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES SRL (IT) | 2014-07-09 | — | — | EP | disclosed |
| US-8114865-B2 | Indazole derivatives as kinase inhibitors for the treatment of cancer | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-14 | — | — | US | disclosed |
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-08-05 | — | — | US | disclosed |
| CN-101594862-A | Substituted indazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2009-12-02 | — | — | CN | disclosed |
| EP-2120932-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Nerviano Medical Sciences S.r.l. (IT) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008074749-A9 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES SRL (IT) | 2009-05-07 | — | — | WO | disclosed |
| WO-2008074749-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | MAP3K5, MAP3K19, MAP3K3 | JAK2 238/4885PDPK1 40/4885KDM4E 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.